HDA Statement on FDA Authorization of Moderna COVID-19 Vaccine
ARLINGTON, Va., December 18, 2020 — HDA President and CEO Chester “Chip” Davis, Jr., released a statement following the U.S. Food and Drug Administration’s (FDA) granting of an Emergency Use Authorization for the Moderna COVID-19 vaccine candidate:
“Today marks another significant step in our nation’s response to COVID-19 that will allow for more Americans to receive a vaccine in the coming months under the direction of the Centers for Disease Control and Prevention (CDC), states and public health experts. HDA appreciates the tireless work of our manufacturer trading partners, FDA, CDC and Operation Warp Speed to advance two vaccine candidates so quickly.
About the Healthcare Distribution Alliance
The Healthcare Distribution Alliance (HDA) represents primary pharmaceutical distributors — the vital link between the nation’s pharmaceutical manufacturers and pharmacies, hospitals, long-term care facilities, clinics and others nationwide. Since 1876, HDA has helped members navigate regulations and innovations to get the right medicines to the right patients at the right time, safely and efficiently. The HDA Research Foundation, HDA’s non-profit charitable foundation, serves the healthcare industry by providing research and education focused on priority healthcare supply chain issues.